Omada Health (NASDAQ:OMDA) CFO Steven Cook Sells 1,607 Shares

Posted by George Bondi on Aug 13th, 2026

Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CFO Steven Cook sold 1,607 shares of Omada Health stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.01, for a total value of $40,191.07. Following the transaction, the chief financial officer directly owned 187,209 shares in the company, valued at approximately $4,682,097.09. The trade was a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Omada Health Trading Down 0.7%

Shares of NASDAQ:OMDA opened at $23.84 on Thursday. The stock has a 50 day moving average of $20.74 and a 200 day moving average of $16.38. The company has a market cap of $1.46 billion, a PE ratio of 476.80 and a beta of 1.73. Omada Health, Inc. has a 12-month low of $10.28 and a 12-month high of $26.92.

Omada Health (NASDAQ:OMDA – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.10. Omada Health had a net margin of 1.39% and a return on equity of 2.67%. The company had revenue of $87.83 million for the quarter, compared to analysts’ expectations of $80.93 million. Equities research analysts predict that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on OMDA. BTIG Research lifted their price objective on Omada Health from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday. Evercore reiterated an “outperform” rating and set a $20.00 target price on shares of Omada Health in a research report on Friday, May 8th. Barclays raised their target price on shares of Omada Health from $20.00 to $25.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Weiss Ratings raised shares of Omada Health from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Tuesday. Finally, Citigroup reiterated an “outperform” rating on shares of Omada Health in a research report on Monday, July 20th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $25.75.

View Our Latest Analysis on Omada Health

Institutional Investors Weigh In On Omada Health

Several large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC bought a new stake in shares of Omada Health in the 2nd quarter valued at approximately $637,000. Walleye Capital LLC bought a new position in shares of Omada Health during the 2nd quarter valued at approximately $458,000. Ilex Capital Partners UK LLP bought a new position in shares of Omada Health during the 2nd quarter valued at approximately $201,000. Soros Fund Management LLC purchased a new stake in Omada Health during the 2nd quarter valued at $640,000. Finally, Raymond James Financial Inc. bought a new stake in Omada Health in the second quarter worth $32,000.

Key Omada Health News

Here are the key news stories impacting Omada Health this week:

Positive Sentiment: Q2 earnings beat expectations. Omada reported earnings of $0.08 per share, compared with the consensus estimate of a $0.02 loss. Revenue reached approximately $87.8 million, exceeding estimates of $80.9 million. The results indicate that growth in the company’s digital chronic-care business is increasingly translating into profitability. Omada Health Q2 earnings analysis
Positive Sentiment: Analysts raised their price targets. Robert W. Baird increased its target from $15 to $25 while maintaining a neutral rating. Other recent targets include $27 from Citizens JMP and $35 from BTIG, supporting a broader consensus “Moderate Buy” rating with an average target near $25.67.
Positive Sentiment: Institutional interest has expanded. Perceptive Advisors and BlackRock established new positions during the second quarter, while Millennium Management significantly increased its stake. These investments may provide support by signaling growing institutional confidence in Omada’s outlook.
Neutral Sentiment: Short interest is effectively nonexistent. Reported short interest was zero shares, offering no meaningful short-covering catalyst but also indicating limited bearish positioning.
Negative Sentiment: Several senior executives sold shares. CEO Sean Duffy sold 21,570 shares across two transactions, CFO Steven Cook sold 16,842 shares, President Wei-Li Shao sold 8,866 shares, and Chief Accounting Officer Craig Gracey sold 1,042 shares. The sales totaled approximately $1.16 million, mostly near $25 per share. Although the transactions may reflect personal liquidity or compensation planning, concentrated selling by top executives can weigh on investor sentiment.
Negative Sentiment: Valuation leaves little room for disappointment. Omada’s market capitalization is approximately $1.46 billion and its reported price-to-earnings ratio is above 475. With shares near the top of their 52-week range, investors may be taking profits despite the earnings beat, particularly while analysts such as Baird remain neutral.

Omada Health Company Profile

(Get Free Report)

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.